SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-007613
Filing Date
2023-03-13
Accepted
2023-03-13 06:03:01
Documents
12
Period of Report
2023-03-13
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K auph-20230313.htm   iXBRL 8-K 33664
  Complete submission text file 0001628280-23-007613.txt   168595

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT auph-20230313.xsd EX-101.SCH 1936
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT auph-20230313_lab.xml EX-101.LAB 23924
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT auph-20230313_pre.xml EX-101.PRE 12622
6 EXTRACTED XBRL INSTANCE DOCUMENT auph-20230313_htm.xml XML 10830
Mailing Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8
Business Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8 250-708-4272
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36421 | Film No.: 23725548
SIC: 2834 Pharmaceutical Preparations